What are the prevalence and association of tumor protein p53 (TP53) and ataxia-telangiectasia mutated (ATM) comutation with response to immune checkpoint inhibitors in patients with non–small cell lung cancer (NSCLC)? This evidence concerns the gene TP53 and non-small cell lung carcinoma.